Key Highlights

  • Haemonetics (NYSE:HAE) rose 15.89% on October 8, 2026 to USD 117.87 in published market data, implying a prior close near USD 101.71, simple arithmetic, after a company disclosure on its CSL Plasma Supply agreement.
  • CSL expects to complete the rollout of Haemonetics devices and disposables by the end of calendar 2027 and anticipates the transition at all of its current US plasma collection centers, per the 8-K.
  • The August 2026 agreement is non-exclusive and contains no minimum purchase commitments, and Haemonetics (NYSE:HAE) is not updating fiscal 2027 guidance until its second quarter call in November 2026.
  • Haemonetics (NYSE:HAE) reported first quarter fiscal 2027 Revenue of USD 339.4 million, up 5.6%, with Plasma revenue of USD 155.5 million, up 7.2%, and adjusted EPS of USD 1.14.

What the 8-K Said

Haemonetics furnished an 8-K on October 8, 2026 under its Regulation FD item. It recalled the supply agreement with CSL Plasma, first disclosed on August 18, 2026, that lets CSL use Haemonetics NexSys PCS devices with Persona PLUS technology and buy related disposables in the United States. The new filing said CSL expects to complete the rollout by the end of calendar 2027 and anticipates the transition will occur at all of its current US plasma collection centers. Scope and timing remain subject to change, and implementation details are still to be set between the two companies. No dollar value, Volume or unit count was given.

Why a Rollout Matters

Plasma collection centers use devices that separate plasma from blood and single-use disposables for every donation, so a device footprint can create recurring disposable demand. Haemonetics (NYSE:HAE) already reported Plasma revenue of USD 155.5 million in the quarter ended June 27, 2026, about 46% of USD 339.4 million total revenue, simple arithmetic. In August the company raised fiscal 2027 guidance to reported revenue growth of 5% to 8% and organic growth of 4% to 7%. Adjusted Operating Margin was 23.4%, down 70 basis points, and cash stood at USD 223.4 million. A full CSL rollout could be material, but the filing does not quantify it.

Risks and What to Watch

The agreement is non-exclusive with no minimum purchases, so actual disposable volumes depend on CSL's execution and may differ from the headline. Timing could slip, and the company has said the financial effect is not yet in guidance. The stock's RSI of about 75 in published market data signals stretched momentum, not a sell signal. Investors in Haemonetics (NYSE:HAE) should watch the second quarter Earnings on November 5, 2026, where management plans to explain the effect on fiscal 2027, plus any detail on pricing, the pace of conversion at CSL centers, the mix of devices versus disposables, and how competitors respond to a customer concentrating its device purchasing.

Where Things Stand

Haemonetics (NYSE:HAE) jumped because CSL said it expects to move all of its current US plasma centers to Haemonetics devices and disposables by the end of calendar 2027, a bigger scope than the August announcement conveyed. The financial effect is unquantified, the agreement has no minimum purchase commitments and guidance is unchanged for now. The balance of evidence is positive on Demand visibility and unproven on dollars. The next catalyst is the November 5, 2026 earnings call.